Company News

Share this article:
Gilead Sciences closing two cardiovascular-focused research and development offices in Colorado. The closures stem from Gilead's acquisition of California-based CV Therapeutics, according to an Associated Press report. A spokesperson for Gilead said the company is consolidating its operations in California.

AstraZeneca partnered with Forest Laboratories for the development and commercialization of ceftaroline, an experimental antibiotic. The partnership includes markets outside of the US, Canada and Japan. Financial terms of the deal were not disclosed.   

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.